Author: Alebund

June 25, 2024, Shanghai, China—Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to AP306 for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).

Continue reading Alebund’s Innovative Investigational Drug AP306 Receives NMPA’s Breakthrough Therapy Designation (BTD) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease (CKD)

• In the completed phase 2 study (NCT05764590), AP306 monotherapy significantly reduced serum phosphate and substantially improved the serum phosphate control rate in hemodialysis patients with hyperphosphatemia. AP306 was safe and well-tolerated.
• Alebund is actively advancing further clinical development of AP306.

May 27, 2024, Shanghai, China—Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, presented the phase 2 study results of AP306 in hemodialysis patients with hyperphosphatemia through the Focused Oral at the 61st European Renal Association (ERA) Congress in Stockholm, Sweden.

Continue reading Alebund Presents Phase 2 Trial Results of AP306 at the 61st European Renal Association (ERA) Congress

March 29, 2024, Shanghai, China – Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AP303 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

Continue reading Alebund’s Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

December 13, 2023, Shanghai, China—Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced phase II proof-of-concept study results for the investigational drug, AP306, a first-in-class, pan-inhibitor of sodium-dependent phosphate transporters, which was discovered by Chugai Pharmaceutical Co., Ltd., and previously referred by EOS789.

Continue reading Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase 2 Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis

July 17 2023, Shanghai, China — Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced that the first patient was enrolled and dosed on June 30 in its phase 3 trial “a randomized, open-label, multicenter phase 3 study to evaluate the efficacy and safety of AP301 on serum phosphorus control in dialysis patients with hyperphosphatemia ”(AP301-HP-02 Phase 3 Clinical Trial). Clinical trial information is available at www.chinadrugtrials.org.cn with identifier CTR20231624. Professor Li ZUO, Director of Department of Nephrology at Peking University People’s Hospital, acts as the leading investigator of the AP301 pivotal phase 3 clinical trial. The trial will be conducted in 50 sites and plan to enroll 472 hyperphosphatemia patients, among which 90% on hemodialysis and 10% on peritoneal dialysis.

Continue reading Alebund Achieved First Patient Enrolment for AP301 Pivotal Phase 3 Clinical Trial and Successfully Held Investigator Meeting in Beijing

Shanghai, China, April 12th, 2023—Alebund Pharmaceuticals (“Alebund” or the “Company”) announced that it has closed its Pre-C round financing, with close to RMB 200 million. Participants in this round include Yangzhou Guojin Investment, Jiangsu Dingxin Capital, Yangzhou Longchuan Holdings a leading international sovereign fund, Lilly Asia Venture, Quan Capital, 3H Health, Octagon Capital, and Verition Fund.

Continue reading Alebund Pharmaceuticals Closes Nearly RMB 200 Million Pre-C Round Financing and Secures RMB 800 Million Syndicated Loan Credit

March 17, 2023, Shanghai, China—Alebund Pharmaceuticals (“Alebund” or the “Company”) announced that China’s National Medical Products Administration (NMPA) has granted approval for the company’s IND application for a phase 3 study of AP301 to treat hyperphosphatemia in dialysis patients.

Continue reading China’s NMPA Clears Phase 3 IND Application for Alebund Pharmaceutical’s AP301, a New-generation Iron-based Phosphate Binder, to Treat Hyperphosphatemia in Dialysis Patients

Yangzhou, China, Dec. 7, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, held today a groundbreaking ceremony for its research and production plant in Jiangsu province’s Yangzhou city.

Continue reading Alebund Pharmaceuticals Holds Groundbreaking Ceremony for Yangzhou Research and Production Base